Horizon Kinetics Asset Management LLC Boosts Stake in Alkermes plc (NASDAQ:ALKS)

Horizon Kinetics Asset Management LLC lifted its holdings in Alkermes plc (NASDAQ:ALKS) by 4.4% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,033 shares of the company’s stock after buying an additional 967 shares during the period. Horizon Kinetics Asset Management LLC’s holdings in Alkermes were worth $662,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Centiva Capital LP bought a new position in Alkermes in the 3rd quarter valued at $367,000. Natixis Advisors LLC grew its position in Alkermes by 190.3% during the third quarter. Natixis Advisors LLC now owns 36,490 shares of the company’s stock valued at $1,021,000 after buying an additional 23,921 shares during the period. Sanctuary Advisors LLC increased its holdings in Alkermes by 254.5% during the third quarter. Sanctuary Advisors LLC now owns 32,791 shares of the company’s stock worth $944,000 after buying an additional 23,541 shares during the last quarter. BNP Paribas Financial Markets raised its position in Alkermes by 74.7% in the third quarter. BNP Paribas Financial Markets now owns 149,493 shares of the company’s stock worth $4,184,000 after acquiring an additional 63,939 shares during the period. Finally, Barclays PLC boosted its stake in Alkermes by 108.8% in the third quarter. Barclays PLC now owns 423,931 shares of the company’s stock valued at $11,867,000 after acquiring an additional 220,893 shares during the last quarter. 95.21% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on ALKS shares. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Alkermes in a report on Tuesday, February 11th. They issued a “buy” rating and a $40.00 price target on the stock. Royal Bank of Canada began coverage on Alkermes in a research report on Thursday, March 13th. They set a “sector perform” rating and a $40.00 price target on the stock. HC Wainwright reissued a “neutral” rating and issued a $46.00 price objective on shares of Alkermes in a report on Thursday, February 13th. StockNews.com raised shares of Alkermes from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 13th. Finally, UBS Group upgraded shares of Alkermes from a “sell” rating to a “neutral” rating and lifted their target price for the stock from $21.00 to $38.00 in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $38.46.

Alkermes Stock Performance

NASDAQ:ALKS opened at $34.37 on Tuesday. The firm has a market capitalization of $5.59 billion, a price-to-earnings ratio of 15.84, a P/E/G ratio of 2.20 and a beta of 0.62. The stock has a fifty day moving average of $32.50 and a 200 day moving average of $29.90. Alkermes plc has a 52-week low of $22.90 and a 52-week high of $36.45.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. Equities analysts forecast that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Craig C. Hopkinson sold 144,419 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the transaction, the executive vice president now directly owns 57,875 shares in the company, valued at approximately $2,056,298.75. This represents a 71.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.89% of the company’s stock.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.